James C Foster Charles River Laboratories International, Inc. (CRL) insider trading activity

James C Foster is Chairman, President and CEO of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Currently has a direct ownership of 184,783 shares of CRL, which is worth approximately $36.2 Million. The most recent transaction as insider was on Nov 08, 2024, when has been sold 4,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 185K

0.52% 3M change

8.81% 12M change

Total Value Held $36.2 Million

JAMES C FOSTER Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 08 2024	SELL Bona fide gift	-	4,500 Reduced 2.38%	184,783 Common Stock
Aug 12 2024	SELL Bona fide gift	-	2,500 Reduced 1.33%	185,751 Common Stock
Aug 01 2024	SELL Open market or private sale	$6,250,000 $250.0 p/Share	25,000 Reduced 11.72%	188,251 Common Stock
May 29 2024	SELL Payment of exercise price or tax liability	$273,285 $214.51 p/Share	1,274 Reduced 0.57%	223,044 Common Stock
Feb 16 2024	SELL Bona fide gift	-	4,000 Reduced 1.75%	224,613 Common Stock
Jan 29 2024	SELL Payment of exercise price or tax liability	$2,369,551 $220.28 p/Share	10,757 Reduced 4.49%	228,613 Common Stock
Jan 29 2024	SELL Payment of exercise price or tax liability	$2,854,157 $224.56 p/Share	12,710 Reduced 5.58%	215,117 Common Stock
Jan 29 2024	BUY Grant, award, or other acquisition	-	24,253 Added 9.2%	239,370 Common Stock
Jan 29 2024	BUY Exercise of conversion of derivative security	$2,522,466 $144.67 p/Share	17,436 Added 7.11%	227,827 Common Stock
Nov 14 2023	BUY Open market or private purchase	$1,000,641 $178.05 p/Share	5,620 Added 2.7%	202,643 Common Stock
Aug 10 2023	SELL Bona fide gift	-	2,500 Reduced 1.25%	197,023 Common Stock
May 29 2023	SELL Payment of exercise price or tax liability	$247,308 $194.12 p/Share	1,274 Reduced 0.63%	199,523 Common Stock
Feb 22 2023	SELL Payment of exercise price or tax liability	$441,890 $243.6 p/Share	1,814 Reduced 0.84%	214,780 Common Stock
Feb 15 2023	SELL Open market or private sale	$5,001,600 $250.08 p/Share	20,000 Reduced 8.45%	216,594 Common Stock
Jan 27 2023	SELL Payment of exercise price or tax liability	-	21,453 Reduced 8.43%	232,922 Common Stock
Jan 27 2023	BUY Grant, award, or other acquisition	-	49,725 Added 16.35%	254,375 Common Stock
Jun 06 2022	SELL Bona fide gift	-	2,000 Reduced 0.94%	211,711 Common Stock
May 29 2022	SELL Payment of exercise price or tax liability	$320,422 $244.41 p/Share	1,311 Reduced 0.61%	213,711 Common Stock
Feb 23 2022	SELL Open market or private sale	$5,883,405 $289.88 p/Share	20,296 Reduced 8.62%	215,022 Common Stock
Feb 23 2022	SELL Payment of exercise price or tax liability	$512,557 $289.58 p/Share	1,770 Reduced 0.82%	215,022 Common Stock
Feb 23 2022	BUY Exercise of conversion of derivative security	$2,219,165 $109.34 p/Share	20,296 Added 7.94%	235,318 Common Stock
Feb 22 2022	SELL Payment of exercise price or tax liability	$472,712 $293.61 p/Share	1,610 Reduced 0.74%	216,792 Common Stock
Feb 22 2022	SELL Open market or private sale	$5,045,455 $289.37 p/Share	17,436 Reduced 7.44%	216,792 Common Stock
Feb 22 2022	BUY Exercise of conversion of derivative security	$2,522,466 $144.67 p/Share	17,436 Added 6.93%	234,228 Common Stock
Feb 15 2022	SELL Open market or private sale	$6,415,400 $320.77 p/Share	20,000 Reduced 8.39%	218,402 Common Stock

JCF

James C Foster

Chairman, President and CEO

Wilmington, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRL shares.

Notify only if

Value

Insider Trading

Get notified when an Charles River Laboratories International, Inc. insider buys or sells CRL shares.

Notify only if

Operation

Value

Type

News

Receive news related to CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Track Activities on CRL

Account